647 results on '"Bianchi, Nicoletta"'
Search Results
152. Polyarginine peptide nucleic acids inhibit biological activity if microRNA 210
153. Increase of microRNA-210, Decrease of Raptor Gene Expression and Alteration of Mammalian Target of Rapamycin Regulated Proteins following Mithramycin Treatment of Human Erythroid Cells
154. Recent trends in the gene therapy of β-thalassemia
155. Generation and Characterization of a Transgenic Mouse Carrying a Functional Humanβ-Globin Gene with the IVSI-6 Thalassemia Mutation
156. Erythroid differentiation induced by mithramycin in K562 cells is associated with inhibition of the mTOR-C1 pathway
157. Generation and molecular characterization of a transgenic mouse line carrying a mutated human IVS-I-6 thalassemia beta-globin gene
158. Mithramycin-mediated induction of K562 cell erythroid differentiation is associated with inhibition of the mTOR-CI patway
159. Peptide nucleic acids targeting β-globin mRNAs selectively inhibit hemoglobin production in murine erythroleukemia cells
160. Production of β-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β°39 thalassemia patients
161. Following β-globin gene transfer, the production of hemoglobin depends upon the β-thalassemia genotype
162. Use of rapamycin and structural analogues thereof
163. Fetal Hemoglobin Inducers from the Natural World: 5 A Novel Approach for Identification of Drugs for the Treatment of b-Thalassemia and Sickle-Cell Anemia
164. Production of s-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous s039 thalassemia patients
165. Drug for treating thalassemia, falciform anemia and all other forms of anemia treatable therewith
166. Heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin A for treatment of beta-thalassemia
167. Farmaco per la cura della talassemia, anemia falciforme e di tutte le altre forme di anemia trattabili con questo, metodo di attivazione del farmaco, composizione farmaceutica avente come principio attivo il farmaco e metodo fotochemioterapico utilizzante il farmaco
168. Synthetic oligonucleotides as inducers of erythroid differentiation
169. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients
170. Everolimus quale induttore di mRNA per la globina gamma nel trattamento della beta-talassemia
171. Increase of the expression of gamma-globin gene in human erytroid cells treated with psoralens
172. In vitro antiproliferative effects on human tumor cell lines of extracts from the Bangladeshi medicinal plant Aegle marmelos Correa
173. Production of a cellular model for the screening of inducers of fetal haemoglobin
174. Increase of accumulationof gamma-globin mRNA in human erythroid cells treated with psoralens
175. Induction of accumulation of gamma-globin mRNA in human erythroid cells treated with psoralens
176. An Aγ-globin G->A gene polymorphism associated with β039 thalassemia globin gene and high fetal hemoglobin production.
177. Oligonucleotidi sintetici a dopio filamento utili nell'induzione di apoptosi di osteoclasti per il trattamento di patologie osteopeniche
178. Induction of accumulation of gamma-globin mRNA in human erythroid cells treated with psoralens
179. Differential expression of A3 adenosine receptors in colorectal cancer and related mucosa: a mirror in blood cells
180. Induction of apoptosis of human osteoclasts by a decoy molecule against a negative regulator of Estrogen Receptor alpha transcription
181. Novel biological activity of psoralens. Induction of accumulation of g-globin mRNA in human erythroid cells
182. Structure and Biological Activity of Furocoumarins
183. Accumulation of gamma-globin mRNA in human erythroid cells treated with angelicin
184. Use of hetrocyclic and benzohetrocyclic polyamides structurally related to the natural antibiotic distamycin A for the treatment of beta-thalassemia
185. Use of angelicin and of its structural analogues for the treatment of thalassemia
186. A NOVEL USE OF RAPAMYCN AND STRUCTURAL ANALOGUES THEREOF
187. Nuovo uso della rapamicina e di suoi analoghi strutturali
188. Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic dystamycin A for the treatment of beta-thalassemia
189. Nuovo uso dell'angelicina e di suoi analoghi strutturali
190. Nuovo impiego di poliammidi eterocicliche e benzoeterocicliche strutturalmente correlate all'antibiotico naturale Distamicina A
191. Oligonucleotidi sintetici in grado di indurre il differenziamento eritroide
192. Glucidic esters of branced carboxylic acids capable of inducing erythroid cellular differentiation
193. Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter
194. Pyrazolo-Triazole Photonucleases as Light Activable DNA Cleaving Agents
195. High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
196. Inhibition of miRNA Maturation by Peptide Nucleic Acids.
197. Molecular Methods for Validation of the Biological Activity of Peptide Nucleic Acids Targeting MicroRNAs.
198. Targeting of the Sp1 binding sites of HIV-1 long terminal repeat with chromomycin. Disruption of nuclear factor-DNA complexes and inhibition of in vitro transcription
199. Cellular Uptakes, Biostabilities and Anti-miR-210 Activities of Chiral Arginine-PNAs in Leukaemic K562 Cells
200. Therapeutic Hemoglobin Levels after Gene Transfer in β-Thalassemia Mice and in Hematopoietic Cells of β-Thalassemia and Sickle Cells Disease Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.